Use of neuronal nitric oxide synthase inhibitors for immunotherapy in melanoma patients
US12083113B2 · kind B2 · utility
0Cited by
34References
24Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 12, 2022 |
| Grant date | Sep 10, 2024 |
| Priority date | — |
| Expiry date | Sep 12, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/2818
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are methods and compositions for administering immunotherapy to a subject in need thereof and for treating a subject in need thereof, where in the methods the subject is administered an effective amount of an inhibitor of nNOS for inducing an immunotherapeutic response in the subject and for treating the subject. The disclosed methods and composition may be utilized for treating a subject having a cell proliferative disease or disorder such as melanoma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.